Publications by authors named "Florence Thoret-Bauchet"
Background: Multidrug-resistant tuberculosis (MDR-TB) represents a major public health concern, with an ongoing need for new effective treatments. Bedaquiline is an oral diarylquinoline that has shown encouraging treatment success and culture conversion rates in MDR-TB.
Methods: A South Korean patient registry was set up across 19 centres between 2016 and 2018 for the prospective collection of data from patients with MDR-TB who received either a bedaquiline-containing or a non-bedaquiline-containing regimen.
Background: This retrospective cohort study assessed benefits and risks of bedaquiline treatment in multidrug-resistant-tuberculosis (MDR-TB) combination therapy by evaluating safety, effectiveness, drug utilization and emergence of resistance to bedaquiline.
Methods: Data were extracted from a register of South African drug-resistant-tuberculosis (DR-TB) patients (Electronic DR-TB Register [EDRWeb]) for newly diagnosed patients with MDR-TB (including pre-extensively drug-resistant [XDR]-TB and XDR-TB and excluding rifampicin-mono-resistant [RR]-TB, as these patients are by definition not multidrug-resistant), receiving either a bedaquiline-containing or non-bedaquiline-containing regimen, at 14 sites in South Africa. Total duration of treatment and follow-up was up to 30 months, including 6 months' bedaquiline treatment.
Article Synopsis
- A multinational, noninterventional study was conducted to analyze the treatment patterns and disease progression in multiple myeloma (MM) patients starting new therapy between October 2010 and October 2012.
- A total of 2,358 patients were enrolled, with 775 undergoing stem cell transplantation (SCT) and 1,583 not, and their treatment histories along with other medical data were collected regularly.
- The study found varying response rates to treatment depending on whether patients underwent SCT and the types of therapies used, with overall response rates ranging from 49% to 97% across different treatment lines.